​

Protagenic Therapeutics Ownership | Who Owns Protagenic Therapeutics?

OverviewRevenueFinancialsChartTranscripts

Protagenic Therapeutics Ownership Summary

Protagenic Therapeutics is owned by 14.16% institutional investors, and 85.84% retail investors. Vanguard Institutional Extnd Mkt Idx Tr is the top mutual fund, with 0.67% of its assets in Protagenic Therapeutics shares.

PTIX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockProtagenic Therapeutics14.16%-85.84%
SectorHealthcare Stocks 49.73%8.84%41.43%
IndustryBiotech Stocks 47.04%8.74%44.21%

Institutional Shareholders

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 20221525.00%611,4302.25%147.40%620.00%4300.00%
Sep 30, 2022129.09%597,947-1.11%137.06%525.00%1-50.00%
Jun 30, 202211-8.33%604,644-10.29%135.72%4-20.00%2-33.33%
Mar 31, 202212-7.69%673,973-29.32%152.34%5-28.57%350.00%
Dec 31, 2021138.33%953,552-0.13%254.84%7-30.00%2100.00%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Institutional Extnd Mkt Idx Tr32.00K0.67%-
Fidelity Extended Market Index17.38K0.39%-2.92K
Fidelity Nasdaq Composite Index5.01K0.11%-
Fidelity Series Total Market Index3.29K0.07%-
NT Ext Equity Mkt Idx Fd - NL3.14K0.07%-
NT Ext Equity Mkt Idx Fd - DC - NL - T22.53K0.06%8.00
Northern Trust Extended Eq Market Idx2.48K0.06%-
NT Ext Equity Mkt Idx Fd - L2.48K0.06%-
State St US Extended Mkt Indx NL Cl C1.23K0.03%-
SSgA U.S. Extended Market Index Class I1.23K0.03%-

Recent Insider Transactions

DateNameRoleActivityValue
Oct 12, 2023Arrow Alexander K. Chief Financial OfficerBuy$6.48K
May 17, 2022Arrow Alexander K. Chief Financial OfficerBuy$16.33K
May 17, 2022Arrow Alexander K. Chief Financial OfficerBuy$5.76K
Jun 02, 2021Arrow Alexander K. Chief Financial OfficerBuy$498.00
Jun 03, 2021Arrow Alexander K. Chief Financial OfficerBuy$84.16K

Insider Transactions Trends

DateBuySell
2023 Q41-
2022 Q21-
2006 Q4-1

PTIX Ownership FAQ

Who Owns Protagenic Therapeutics?

Protagenic Therapeutics shareholders are primarily institutional investors at 14.16%, followed by 0% insiders and 0% retail investors. The average institutional ownership in Protagenic Therapeutics's industry, Biotech Stocks , is 47.04%, which Protagenic Therapeutics falls below.

Does Blackrock own Protagenic Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Protagenic Therapeutics.

Who is the top mutual fund holder of Protagenic Therapeutics shares?

Vanguard Institutional Extnd Mkt Idx Tr is the top mutual fund holder of Protagenic Therapeutics shares, with 0.67% of its total shares outstanding invested in 32K Protagenic Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools